DCAR Inhibitors
DCAR inhibitors are chemical compounds designed to inhibit the function of DCAR (Dendritic Cell Activating Receptor), a protein that plays a role in the immune system, specifically in immune cell activation and communication. DCAR is a member of the C-type lectin receptor family, which is known for recognizing various carbohydrate structures on pathogens and self-cells, leading to cellular signaling processes that activate immune responses. DCAR is expressed primarily on dendritic cells and other immune cells, where it plays a role in recognizing molecular patterns, facilitating antigen uptake, and initiating intracellular signaling cascades that regulate immune function. Structurally, DCAR contains extracellular carbohydrate recognition domains, which allow it to bind to specific ligands, and intracellular domains that are involved in transmitting signals to the immune cell's interior.
Inhibitors of DCAR function by blocking the binding of ligands to the receptor or interfering with the downstream signaling pathways initiated by DCAR activation. These inhibitors may work by targeting the extracellular carbohydrate recognition domain, preventing ligand interaction, or by binding to the intracellular signaling domains, hindering the receptor's ability to propagate activation signals. By disrupting these interactions, DCAR inhibitors can modulate the processes that are dependent on DCAR's activity, such as cellular signaling, immune cell communication, and antigen presentation. The design and development of DCAR inhibitors require a detailed understanding of the receptor's structural biology, including the specific regions responsible for ligand binding and signal transduction. As a result, these inhibitors serve as valuable tools in studying the intricate molecular mechanisms that govern immune cell activation and the broader processes involved in cellular communication and recognition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $91.00 $255.00 | 32 | |
Temozolomide inhibits DNA repair by methylating guanine, inducing apoptosis. Its indirect impact on DCAR involves disrupting DNA damage response pathways, potentially inhibiting the protein's function in sensing and repairing damaged DNA. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair. Its indirect modulation of DCAR involves impairing the repair of DNA damage, potentially influencing the protein's role in monitoring genomic integrity. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
ATR Inhibitor (VE-821) inhibits the ATR kinase, disrupting DNA damage response pathways. Its indirect influence on DCAR involves hindering ATR-mediated signaling, potentially impacting the protein's function in sensing and responding to DNA damage. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin forms DNA adducts, causing DNA crosslinking and apoptosis. Its indirect impact on DCAR involves inducing DNA damage, potentially affecting the protein's role in monitoring and responding to genotoxic stress. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits topoisomerase II, causing DNA strand breaks and apoptosis. Its indirect modulation of DCAR involves inducing DNA damage, potentially influencing the protein's function in monitoring and responding to genotoxic stress. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
AZD6738 inhibits ATR kinase, disrupting DNA damage response pathways. Its indirect influence on DCAR involves impairing ATR-mediated signaling, potentially impacting the protein's function in sensing and responding to DNA damage. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C forms DNA crosslinks, inhibiting DNA replication and inducing apoptosis. Its indirect impact on DCAR involves inducing DNA damage, potentially affecting the protein's role in monitoring and responding to genotoxic stress. | ||||||
NU6027 | 220036-08-8 | sc-215591 | 10 mg | $156.00 | 1 | |
NU6027 inhibits the ATR kinase, disrupting DNA damage response pathways. Its indirect modulation of DCAR involves impairing ATR-mediated signaling, potentially impacting the protein's function in sensing and responding to DNA damage. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin intercalates DNA, causing DNA damage and apoptosis. Its indirect impact on DCAR involves inducing DNA damage, potentially affecting the protein's role in monitoring and responding to genotoxic stress. | ||||||
ATM Kinase Inhibitor | 587871-26-9 | sc-202963 | 2 mg | $110.00 | 28 | |
ATM Kinase Inhibitor disrupts DNA damage response pathways. Its indirect influence on DCAR involves impairing ATM-mediated signaling, potentially impacting the protein's function in sensing and responding to DNA damage. | ||||||